Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.

Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.

Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth.

WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (NASDAQ:TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission ("SEC"), highlighting improved operational efficiency.

For the three months ended June 30, 2025, loss from operations was $5.4 million, compared to $8.6 million for the same period in 2024. Net loss for the quarter was $5.5 million, compared to $9.7 million in Q2 2024.

"In our sector, it is common to see companies incur significantly larger operating losses than Tevogen, yet at Tevogen, every dollar goes a long way as we continue building infrastructure, advancing AI, and strengthening internal capabilities in a market that is otherwise seeing limited growth. We also maintain access to sufficient capital to support our path to anticipated revenue by the end of 2026. At the same time, we recognize that our current limited tradable float does not ...